EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Testing Meningiomas With Methylation Arrays: Insights and Recommendations From a Large Single‐Centre Study

Fernanda Ruiz, Rossella Rispoli, Zane Jaunmuktane iD, Ashirwad Merve, Linda D'Antona, Monika Dutt, Felix Sahm iD, Sebastian Brandner iD

Neuropathology and Applied Neurobiology · 2025

DOI: 10.1111/nan.70018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuropathology and Applied Neurobiology, 2025. Verfasst von Fernanda Ruiz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuropathology, the National Hospital for Neurology and Neurosurgery, University College NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Meningioma, Meningeal Neoplasms, DNA Methylation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Meningiomas are common primary CNS tumours, and their morphological diagnosis is usually straightforward. Their histological grading according to CNS WHO criteria alone provides limited information on recurrence risk. Risk stratification of meningiomas combining WHO grade, methylation class and copy number profile improves prediction of the risk of early recurrence. Because of the frequency of meningiomas in diagnostic practice, applying this prediction algorithm to all meningiomas is financially not viable in most healthcare systems.

Methods

We analysed a retrospective dataset of over 1000 meningiomas from a single centre with methylation arrays to provide guidance on which meningiomas to prioritise for integrated molecular testing and to understand how WHO grades resolve into risk strata.

Results

Approximately 90% of CNS WHO Grade 1 meningiomas were allocated into the methylation class ‘benign’ and also into a low‐risk group. Grade 2 meningiomas were allocated almost equally to either the low‐risk (39%) or intermediate‐risk groups (46%) but occasionally also to the high‐risk group (15%). All grading criteria for CNS WHO Grade 2 meningiomas (brain invasion, mitotic count, cytoarchitectural atypia and histological type) showed a similar risk score distribution as the entire group. Grade 3 meningiomas were allocated to intermediate‐ (26%) or high‐risk groups (74%).

Conclusion

Our data suggest that Grade 2 and 3 meningiomas should be prioritised for methylation profiling. A small proportion of Grade 1 meningiomas may also benefit from integrated molecular analysis, and further research is needed to explore if those histologically benign meningiomas with a predicted increased recurrence risk are associated with distinct demographic or histological characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeningiomaMeningeal NeoplasmsDNA MethylationHumansFemaleMaleRetrospective StudiesMiddle AgedAgedAdultNeoplasm GradingAged, 80 and over

Stichwörter der Autor:innen

CNS WHO gradingmeningiomamethylation arraymodel scoreprognostication

Autor:innen und Institutionen

  • Division of Neuropathology, the National Hospital for Neurology and Neurosurgery, University College NHS Foundation Trust, London, UK.
  • Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
  • Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.
  • Department of Histopathology, Great Ormond Street Hospital, London, UK.
  • Division of Neurosurgery, the National Hospital for Neurology and Neurosurgery, University College Hospitals NHS Foundation Trust, London, UK.
  • Dept. of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.

ORCID-Profile: Zane Jaunmuktane, Felix Sahm, Sebastian Brandner

Förderung

  • National Institute for Health and Care Research

Zitieren

APA

Ruiz, F., Rispoli, R., Jaunmuktane, Z., Merve, A., D'Antona, L., Dutt, M., Sahm, F., & Brandner, S. (2025). Testing Meningiomas With Methylation Arrays: Insights and Recommendations From a Large Single‐Centre Study. Neuropathology and Applied Neurobiology. https://doi.org/10.1111/nan.70018

Vancouver

Ruiz F, Rispoli R, Jaunmuktane Z, Merve A, D'Antona L, Dutt M, et al. Testing Meningiomas With Methylation Arrays: Insights and Recommendations From a Large Single‐Centre Study. Neuropathology and Applied Neurobiology. 2025. doi:10.1111/nan.70018

BibTeX
@article{Ruiz2025,
  author = {Ruiz, Fernanda and Rispoli, Rossella and Jaunmuktane, Zane and Merve, Ashirwad and D'Antona, Linda and Dutt, Monika and Sahm, Felix and Brandner, Sebastian},
  title = {Testing Meningiomas With Methylation Arrays: Insights and Recommendations From a Large Single‐Centre Study},
  journal = {Neuropathology and Applied Neurobiology},
  year = {2025},
  doi = {10.1111/nan.70018}
}
Kostenlos starten →